Impaired ζ chain expression and IFN-γ production in peripheral blood T and NK cells of patients with advanced lung cancer

被引:28
作者
Ciszak, Lidia [1 ]
Kosmaczewska, Agata [1 ]
Werynska, Bozena [2 ]
Szteblich, Aleksandra [1 ]
Jankowska, Renata [2 ]
Frydecka, Irena [1 ,3 ]
机构
[1] Polish Acad Sci, Inst Immunol & Expt Therapy, Dept Expt Therapy, PL-53114 Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Pulmonol & Lung Canc, PL-53439 Wroclaw, Poland
[3] Wroclaw Med Univ, Dept Haematol, PL-50367 Wroclaw, Poland
关键词
small cell lung cancer; non-small cell lung cancer; zeta chain; IFN-gamma; chemotherapy; T cells; NK cells; NATURAL-KILLER-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; SIGNAL-TRANSDUCING MOLECULES; DECREASED EXPRESSION; DOWN-REGULATION; RECEPTOR; ABNORMALITIES; CARCINOMA; CD3-ZETA; BREAST;
D O I
10.3892/or_00000205
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Recent studies show that low expression of chain in T and NK cell leads to impaired anti-tumour immunity in patients with cancer, poor prognosis, and shorter overall survival. Therefore, monitoring chain expression may be useful in assessing immune competence in]Ling cancer patients and in following changes during anticancer therapies. Such studies concerning small-cell and non-small cell lung cancer (SCLC and NSCLC, respectively) have not been published so far. The expression of zeta chain and IFN-gamma in peripheral blood (PB) T and NK cells from SCLC and NSCLC patients at advanced (III, IV) stages were analysed before and after chemotherapy with etoposide and cisplatin using flow cytometry. Serum concentrations of TGF-beta 1 and IL-10 were also estimated at each time point tested. Before therapy, impaired chain expression was observed in all the patients corresponding with increased levels of immuno-suppressive cytokines in sera compared with controls. Decreased IFN-gamma production in T cells from all patients was also demonstrated. In NK cells, IFN-gamma was secreted at lower levels in NSCLC patients, while in the SCLC group it was normal. After chemotherapy, restoration of expression in NK cells and its insignificant increase in T cells in SCLC patents corresponding with normalization of TGF-beta secretion were noted. In contrast, NSCLC patients retained impaired expression in T and NK cells. SCLC and NSCLC patients showed a profound defect in IFN-gamma secretion in T and NK cells upon treatment. There were no differences in studied parameters between NSCLC and SCLC groups before and after chemotherapy. This is the first report of impaired expression in PB T and NK cells in patients with SCLC and NSCLC in advanced stages, which may result from higher levels of immunosuppressive cytokines in sera. After cytostatic treatment, all the studied patients, including those with initial good response to chemotherapy, remained with profound abnormalities in T and NK cells, which could have dramatic consequences regarding severely impaired anti-tumour immunity.
引用
收藏
页码:173 / 184
页数:12
相关论文
共 54 条
[1]
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [J].
Ahmad, M ;
Rees, RC ;
Ali, SA .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (10) :844-854
[2]
ALBERTI W, 1995, BRIT MED J, V311, P899
[3]
IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ [J].
Beatty, GL ;
Paterson, Y .
JOURNAL OF IMMUNOLOGY, 2001, 166 (04) :2276-2282
[4]
Human natural killer cell receptors and co-receptors [J].
Biassoni, R ;
Cantoni, C ;
Pende, D ;
Sivori, S ;
Parolini, S ;
Vitale, M ;
Bottino, C ;
Moretta, A .
IMMUNOLOGICAL REVIEWS, 2001, 181 :203-214
[5]
Bukowski RM, 1998, CLIN CANCER RES, V4, P2337
[6]
Evidence for immune defects in breast and lung cancer patients [J].
Caras, I ;
Grigorescu, A ;
Stavaru, C ;
Radu, DL ;
Mogos, I ;
Szegli, G ;
Salageanu, A .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (12) :1146-1152
[7]
Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients [J].
Choi, SH ;
Chung, EJ ;
Whang, DY ;
Lee, SS ;
Jang, YS ;
Kim, CW .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 45 (06) :299-305
[8]
Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress [J].
Chute, JP ;
Chen, T ;
Feigal, E ;
Simon, R ;
Johnson, BE .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1794-1801
[9]
FINKE JH, 1993, CANCER RES, V53, P5613
[10]
Fischer AR, 2004, LUNG CANCER, V45, pS151, DOI 10.1016/j.lungcan.2004.07.000